netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 Formulary Chapter 12: Ear, nose and oropharynx - Full Chapter

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

12.03.04  Expand sub section  Mouthwashes, gargles, and dentifrices
Chlorhexidine gluconate mouthwash 0.2%
View adult BNF View SPC online
Hydrogen peroxide mouth wash BP
View adult BNF View SPC online
Formulary Strengths avaialble:
  • 3% (10 volume)
  • 6% (20 volume) 
    Sodium chloride mouthwash, compound BP
    View adult BNF View SPC online
    Formulary Contains:
  • Sodium bicarbonate 1%
  • Sodium choride 1.5% 
    Thymol Mouthwash Solution-tablets
    View adult BNF View SPC online
    OM1 antimicrobial soution
    Unlicensed Drug Unlicensed

    To be used under the supervision of a Consultant in Oral Microbiology or Oral Medicine only

    Treatment of the following conditions where coliforms and other microorganism counts are high and the patient is symptomatic:

    • Exfoliative cheilitis chronic mucocutaneous candidiasis (CMCC)
    • Oral infections caused by Gram negative rods e.g. E. coli & proteus spp.

    PIL available on GTi

    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Track Changes
    Display tracking information
    click to search
    Link to adult BNF
    click to search
    Link to SPCs
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHS England

    Traffic Light Status Information

    Status Description


    Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

    Amber 1

    Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

    Amber 2

    Specialist initiation followed by maintenance prescribing in primary care  

    Amber 3

    Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  


    Specialist and non-specialist initiation  


    Not recommended for prescribing